Pulmonx last week filed a registration statement signaling its intent to raise $86 million in an IPO after withdrawing it earlier this year.
Redwood City, Calif.-based Pulmonx filed the $86 million IPO in February but withdrew it in May after raising $66 million in a private financing round.
Terms for pricing were not disclosed in the filing, which listed BofA Securities, Morgan Stanley, Stifel, Wells Fargo Securities and Canaccord Genuity as the joint bookrunners for the offering. Pulmonx plans to list on the Nasdaq market under the “LUNG” ticker.
Proceeds from Pulmonx’s last financing round were earmarked for the global commercial expansion efforts for the Zephyr Valve system for severe emphysema, a form of chronic obstructive pulmonary disease (COPD).
The Zephyr Valve system is an FDA-approved minimally invasive treatment option. Its treatment is performed through a bronchoscopy with no incision or tissue resection.